MondayJun 13, 2022 1:16 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Committed to Psilocybin, Anti-Inflammatory Research

Silo Pharma (OTCQB: SILO) still believes in medicinal mushrooms despite the fact that they are currently outlawed by the U.S. government (though legal in Oregon and decriminalized in various cities and states). Recently, the company announced that the Translational Psychedelic Research (“TrPR”) Program at the University of California San Francisco (“UCSF”) had successfully dosed [with psilocybin] patients who have Parkinson’s disease. “Silo is exploring psilocybin’s anti-inflammatory possibilities in patients exhibiting signs of Parkinson’s,” reads a recent article. “Silo’s commitment to psilocybin and anti-inflammatory research includes: executing an option agreement with the University of Maryland, Baltimore, studying novel system-homing peptides that…

Continue Reading

FridayJun 10, 2022 3:16 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Leveraging Profitable Model to Scale Best-in-Class Care Directly to Patients

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, owns and operates an assortment of related businesses and is backed by a team of industry and cannabis veterans. The company’s mission is to provide education, research, high-quality products, and effective treatment options to the masses. “In a January interview, Delic CEO and Co-Founder Matt Stang explained that there are 51.5 million Americans who have experienced a mental health condition, and the ongoing pandemic has only exacerbated the crisis. This increase in mental health issues has led to a stronger demand for alternatives to current treatments with lasting outcomes…

Continue Reading

FridayJun 10, 2022 10:49 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Awarded Board Approval for CYB003 Phase 1/2a Clinical Trial

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, received Institutional Review Board (“IRB”) approval to begin its planned phase 1/2a clinical trial. The trial, the first-in-human phase 1/2a trial evaluating CYBN’s proprietary deuterated psilocybin analog CYB003, is slated to begin in mid-2022.The study will evaluate CYB003 for the treatment of major depressive disorder (“MDD”).  Cybin applied for IRB approval just last month. According to the announcement, Cybin wholly owned subsidiary Cybin IRL Limited has partnered with Clinilabs Drug Development Corporation to conduct the randomized, double-blind, placebo-controlled study. The study involves participants receiving two administrations of…

Continue Reading

TuesdayJun 07, 2022 11:03 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Acquisition of Entheon Biomedical’s DMT Clinical Study

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has entered an agreement to acquire the largest phase 1 DMT study conducted to date. The acquisition, conducted through Cybin IRL Limited, a wholly owned subsidiary of Cybin, is expected to accelerate Cybin’s CYB004 program timeline by an estimated nine months; CYB004 is Cybin’s proprietary deuterated DMT molecule designed for the potential treatment of anxiety disorders.. The phase 1 N,N-dimethyltryptamine (“DMT”) study is focused on evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and is expected to significantly impact the clinical path forward. Renamed CYB004-E, the phase 1 EBRX-101…

Continue Reading

MondayJun 06, 2022 12:46 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Adelia Has Reached Milestone Achievements

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced that Adelia Therapeutics Inc., its wholly owned subsidiary, has achieved significant milestones, which the company identified as Y2, Q2 (i), (vi), Y2, Q3 (ii), Year 2 Q4 (i) and Year 3 Q1 (i), (ii). These milestones are outlined in the Dec. 4, 2021, contribution agreement between Cybin and Adelia; the agreement specifies what actions are to be taken when these milestones are reached. Specifically, when these milestones are met, the agreement calls for class B common shares to be issued to Adelia shareholders; those shares are…

Continue Reading

FridayJun 03, 2022 2:03 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Spotlighted in “Frontiers in Psychology” Article

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its proprietary EMBARK program is the focus of a recent article in the “Frontiers in Psychology” journal. The peer-reviewed article discusses the company’s model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing with psychedelic medicines. Titled “Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model,” the article appears in the June 2, 2022, issue of the publication, which is the largest journal in the field of psychology. The article discusses EMBARK’s…

Continue Reading

ThursdayJun 02, 2022 12:38 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host Webinar Delving into Psychedelics Landscape, Current and Emerging Therapeutics

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that it will host a virtual Key Opinion Leader webinar from 11:00 a.m. to 12:00 p.m. ET on Thursday, June 9, 2022. The webinar will be moderated by Cybin’s Chief Executive Officer Doug Drysdale and will feature two leading experts for a discussion on the psychedelics landscape and current and emerging psychedelic-based therapeutics. Dr. John Krystal, the Robert L. McNeil, Jr., Professor of Translational Research; Professor of Psychiatry, Neuroscience and Psychology; Chair of the Department of Psychiatry at Yale University; and Chief of…

Continue Reading

WednesdayJun 01, 2022 1:14 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Submits IND Application

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life-sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced that it has submitted an investigational new drug (“IND”) application with the U.S. Food and Drug Administration and Health Canada. The application is for the FDS-PEA and includes details of a planned phase 2 clinical trial of the substance for the treatment of a yet-to-be-disclosed inflammatory disorder. The announcement also noted that the company recently completed the sale of its cannabis production facility in Ontario, which completed the company’s departure from the cannabis sector and transition into becoming…

Continue Reading

WednesdayJun 01, 2022 1:09 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Expanding Availability of First-of-Its-Kind Treatment – SPRAVATO(R)

Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) subsidiary Ketamine Wellness Centers (“KWC”) , the largest ketamine therapy provider in the U.S., has expanded the availability of SPRAVATO(R) to three new cities and increased the total number of clinics offering the FDA-approved esketamine nasal spray to six. According to the update, the KWC clinics in Minneapolis, Salt Lake City and Dallas now join the Houston, Las Vegas and Seattle locations in offering SPRAVATO to their patient base. Taken with an oral supplement, SPRAVATO is for adults experiencing treatment-resistant depression (“TRD”) or depressive symptoms associated with major depressive disorder (“MDD”). “KWC…

Continue Reading

TuesdayMay 31, 2022 2:13 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Completion of Annual Filings

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has reported that, further to its news release dated May 16, 2022, the company has filed its annual financial statements, management’s discussion and analysis, and related certifications for the year ended Dec. 31, 2021, (collectively, the “annual filings”). Delic expects that the management cease trade order (the “MCTO”), which was issued on May 3, 2022, will be revoked in the coming days. While the MCTO remains in effect, the general investing public will continue to be able to trade Delic’s securities.…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050